GOLM1 (Golgi membrane protein 1): A Key Culprit in Cancer Progression and Disease Pathogenesis

Abstract

Since the initial discovery of the Golgi apparatus protein’s role in normal cellular function and its association with malignancy, remarkable studies and findings on Golgi proteins have continuously emerged across various cancers. Among these proteins, GOLM1 was first identified by the American scholar Kladney and his colleagues in adult giant cell hepatitis. Over time, GOLM1 has been recognized as one of the most significant proto-oncogenes in multiple cancers. Its diagnostic role in both hepatocellular carcinoma and prostate cancer has yielded crucial results, positioning it as a strong competitor to traditional diagnostic markers in these tumors. Due to its secretory nature, GOLM1 levels can be detected in blood or urine, making it a potential non-invasive diagnostic tool for certain malignancies. Regarding its oncogenic role in cancers such as lung, colon, ovarian and breast cancer, multiple studies have highlighted its involvement in advanced resistant cases, suggesting its potential as a future target for therapy.